Table 5.

ORs and 95% CIs for bladder cancer according to family history of bladder cancer stratified by NAT2 and GSTM1 polymorphisms

GenotypeSubjects with family history of bladder cancer (cases/controls)Subjects without family history of bladder cancer (cases/controls)OR* (95% CI)Pinteraction
NAT2-slow14/3414/4124.76 (1.25-18.09)
NAT2-rapid/intermediate2/4247/3131.17 (0.17-7.86)0.609
GSTM1-null5/2423/3652.91 (0.44-19.09)
GSTM1-present11/5240/3634.21 (1.26-14.14)0.712
  • * After adjustment by unconditional logistic regression for age, gender, area, and smoking status of the subjects and average lifetime trihalomethane levels (μg/L).